<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00544999</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000564068</org_study_id>
    <secondary_id>IRLMS-GOELAMS-RAD001</secondary_id>
    <secondary_id>INCA-RECF0476</secondary_id>
    <nct_id>NCT00544999</nct_id>
  </id_info>
  <brief_title>Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>Phase I Study Evaluating the Chemosensitizing Effect of Everolimus Administered With Cytarabine and Daunorubicin in Patients With Acute Myeloid Leukemia in Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche Clinique sur les Cancers et le Sang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
      dividing. Everolimus may help cytarabine and daunorubicin work better by making cancer cells
      more sensitive to chemotherapy. Giving everolimus together with cytarabine and daunorubicin
      may kill more cancer cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when
      given together with cytarabine and daunorubicin in treating patients with relapsed acute
      myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose of everolimus.

        -  Determine the toxicity of this regimen.

      Secondary

        -  Assess the activation of PI3K/AKT and mTORC 1 in leukemic blasts.

        -  Evaluate the pharmacokinetics of everolimus at different concentrations.

      OUTLINE: This is a multicenter study.

      Patients receive primary induction therapy comprising daunorubicin hydrochloride IV on days
      1-3, cytarabine IV over 24 hours on day 1, and oral everolimus on days 1 and 7. Patients with
      more than 5% blasts on day 15 receive a second induction course comprising daunorubicin
      hydrochloride IV on days 17 and 18 and cytarabine IV twice daily on days 17-20.

      After completion of study therapy, patients are followed for 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of everolimus</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation of PI3K/AKT and mTORC 1 in leukemic blasts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of everolimus</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Diagnosis of de novo or secondary acute myeloid leukemia meeting the following
             criterion:

               -  Relapse &gt; 1 year after obtaining complete remission (any prior treatment allowed)

        Exclusion criteria:

          -  Philadelphia chromosome-positive disease in blast crisis

          -  FAB M3, M6, or M7 disease

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Life expectancy ≥ 4 weeks

          -  Transaminases ≤ 5 times normal

          -  Creatinine ≤ 2 times normal

          -  Bilirubin ≤ 3 times normal (except if visceral involvement present)

          -  Alkaline phosphatase or gamma-glutamyltransferase ≤ 5 times normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients of must use effective contraception during and for ≥ 28 days after
             completion of study therapy

        Exclusion criteria:

          -  FEV1 &lt; 30%

          -  Active uncontrolled or viral pulmonary infection

          -  Serious psychiatric disorders not related to leukemia or any condition that would
             prohibit comprehension of the study

          -  HIV-positive

          -  Other concurrent malignancy except noninvasive skin cancer or carcinoma in situ

          -  Patients who are incarcerated or under supervision or trusteeship

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  See Disease Characteristics

        Exclusion criteria:

          -  Prior experimental medication within the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Park, MD</last_name>
    <affiliation>Institut de Recherche Clinique sur les Cancers et le Sang</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Park, MD</last_name>
      <phone>33-140-514-543</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2007</study_first_submitted>
  <study_first_submitted_qc>October 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2007</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

